ANSES 2025 Nutrivigilance Report Signifies Heightened French Regulatory Scrutiny
France's ANSES has released its 2025 Nutrivigilance Activity Report, highlighting increased surveillance on supplement adverse effects and signalling forthcoming regulatory pressures for manufacturers and brand owners operating in the French market.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 14 October 2026
The French Agency for Food, Environmental and Occupational Health & Safety (ANSES) has published its 2025 Nutrivigilance Activity Report, signed on 9 October 2026. This annual report provides a critical overview of adverse effect declarations linked to the consumption of food supplements, fortified foods, and novel ingredients within the French market. Authored by Audrey Sayaque and falling under the 'Human Food and Nutrition' thematic area, the document signals an intensifying regulatory focus on product safety and consumer protection across France's supplement sector.
The report's release indicates ANSES is systematically consolidating data on undesirable effects. This data collection underpins the agency's subsequent risk assessments and informs regulatory policy. For supplement manufacturers and brand owners, this translates directly into a more stringent evaluation environment for new product introductions and ongoing market surveillance of existing lines. The focus is on identifying patterns of adverse reactions, particularly concerning specific ingredients or combinations, which could trigger safety alerts or recommendations for market withdrawal or reformulation. Historically, ANSES recommendations have often influenced broader EU regulatory dialogue.
Operational implications include the necessity for manufacturers to implement more robust post-market surveillance systems to align with ANSES's data collection efforts. Failure to provide adequate safety documentation or to proactively manage adverse event reporting risks non-compliance penalties and public safety warnings. The report reinforces the agency’s commitment to evidence-based regulation, where product safety profiles are continually re-evaluated against real-world consumption data. This proactive stance contrasts with a reactive approach, demanding greater transparency and due diligence from industry participants.
What this means for France
French brand owners and manufacturers must immediately review their product portfolios against potential heightened scrutiny from ANSES. A proactive assessment of adverse event reporting for products sold in France is critical to mitigate risks of market intervention. Reformulation windows for complex multi-ingredient products are likely to compress, necessitating rapid R&D and supply chain adjustments to meet any new dosage or ingredient restrictions. Competitive positioning will favour companies demonstrating superior post-market surveillance capabilities and transparent safety data, offering a distinct market advantage in a tightening regulatory environment. Expect increased demand for comprehensive toxicological dossiers.
This annual report serves as a definitive indicator of ANSES's strategic priorities for the coming year. Companies should anticipate more detailed guidance on adverse event reporting requirements and ingredient-specific safety thresholds. The trend suggests a move towards stronger regulatory enforcement, with a potential for specific ingredients identified in the 2025 report to face revised authorisation conditions or restrictions. Industry players must integrate this intelligence into their Q4 2026 and H1 2027 strategic planning, focusing on proactive compliance and risk management to maintain market access and consumer trust in France.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.